列纳利多米德调节CCL21/CCR7/ERK1/2轴以抑制扩散大B细胞淋巴瘤的迁移和增殖
1Department of Pathology, Guizhou Medical University, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Oncology research
|December 30, 2024
概括
这项研究确定了化学激素受体CCR7 (C-C化学激素受体7型) 作为使用lenalidomide治疗扩散性大B细胞淋巴瘤 (DLBCL) 的关键因素. 向CCL21/CCR7/ERK1/2通路可能会提高莱纳利多米德在DLBCL中的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 已知化学因子受体CCR7 (C-C化学因子受体型7) 在扩散性大B细胞淋巴瘤 (DLBCL) 的预后意义.
- 在DLBCL中CCR7的机制,特别是它与莱纳利多米德的相互作用,需要进一步阐明.
研究的目的:
- 研究CCR7在DLBCL中的作用及其与莱纳利多米德治疗的相互作用.
- 为了识别用莱纳利多米德治疗的DLBCL细胞系中的枢纽基因和预后因素.
主要方法:
- 用lenalidomide治疗的SU-DHL-2细胞系的生物信息学分析.
- 在122名DLBCL患者样本中对CCR7和p-ERK1/2进行免疫组织化学分析.
- 在体外和体内实验中评估CCR7功能和莱纳利多米德反应.
主要成果:
- 在用莱纳利多米德治疗的DLBCL中,CCR7被确定为枢纽基因.
- 在DLBCL中,CCR7和ERK1/2表达与不良结果相关.
- CCL21/CCR7/ERK1/2轴促进了DLBCL的进展,但受到莱纳利多米德,CCR7沉默或ERK抑制剂的抑制.
- 列纳利多米德在体内减少了瘤生长和CCR7/p-ERK1/2表达.
结论:
- 在DLBCL中,CCL21/CCR7/ERK1/2轴对莱纳利多米德的治疗效果起着作用.
- 在DLBCL中,CCR7是改善lenalidomide治疗的潜在治疗标.
相关概念视频
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
01:45Positive Regulator Molecules
105.5K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.5K
01:23Negative Regulator Molecules
35.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
02:23Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K